Eyes have it: Avalanche Bio inks $640 million-plus Regeneron gene therapy deal

Gene therapy company Avalanche Biotechnologies Inc. struck a deal potentially worth more than $640 million with Regeneron Pharmaceuticals Inc...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.